Terminated trial tested unusual drug mix for tough liver cancers
NCT ID NCT03785210
Summary
This study tested whether combining three existing drugs—nivolumab (an immunotherapy), tadalafil (a blood pressure/erectile dysfunction drug), and oral vancomycin (an antibiotic)—could shrink advanced liver cancers. It was for adults whose liver cancer (either starting in the liver or spread from the colon or pancreas) had not responded to standard treatments. The trial was terminated early and enrolled only 22 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.